Passive surveillance as an instrument to identify risk factors for fatal Rocky Mountain spotted fever: Is there more to learn?

American Journal of Tropical Medicine and Hygiene

Volumn 66, Issue 5, 2002, Pages 450-457

  Childs, James E ^a   Paddock, Christopher D ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORAMPHENICOL; TETRACYCLINE DERIVATIVE;

AGE; ARTICLE; DIAGNOSTIC TEST; DISEASE SEVERITY; HUMAN; LABORATORY DIAGNOSIS; MORTALITY; PARASITE PREVALENCE; PATIENT MONITORING; POLYMERASE CHAIN REACTION; QUANTITATIVE ANALYSIS; RISK FACTOR; ROCKY MOUNTAIN SPOTTED FEVER;

ACARI; PROTOZOA;

EID: 0036561193     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2002.66.450     Document Type: Article

References (64)

1. Studies in pyroplasmosis hominis ('spotted fever' or 'tick fever' of the Rocky Mountains)
2. Rocky Mountain spotted fever
3. Rocky Mountain spotted (tick) fever
4. Rocky Mountain spotted fever (tick fever)
5. Rocky Mountain spotted fever; Montana-Lo Lo District
6. Rocky Mountain spotted or tick fever; California report for March, 1920
7. Surveillance of Rocky Mountain spotted fever
8. Epidemiology of Rocky Mountain spotted fever 1975-1979
9. Rocky Mountain spotted fever: Clinical, laboratory, and epidemiological features of 262 cases
10. Reported incidence of selected notifiable diseases, United States, each division and state, 1920-50
11. The United States Public Health Service and rickettsial diseases: Past, present, future
12. Historical development
13. Rocky Mountain spotted fever: Epidemiology of an increasing problem
14. Tick-borne diseases in the United States: Rocky Mountain spotted fever and Colorado tick fever
15. Computerizing public health surveillance systems
16. National electronic telecommunications system for surveillance-United States, 1990-1991
17. Rocky Mountain spotted fever in the United States during 1993 through 1996
18. National surveillance for Rocky Mountain spotted fever, 1981-1992: Epidemiologic summary and evaluation of risk factors for fatal outcome
19. Surveillance of Rocky Mountain spotted fever in the United States, 1981-1983
20. Case definitions for infectious conditions under public health surveillance
21. Rocky Mountain spotted fever
22. Quantitative analysis of variations in the injury of endothelial cells elicited by 11 isolates of Rickettsia rickettsii
23. Status of the rickettisoses in the United States
24. The treatment of Rocky Mountain spotted fever with particular reference to intravenous fluids: A new approach to basic supportive therapy
25. Rocky Mountain spotted fever in the United States, 1920-1970
26. Analysis of risk factors for fatal Rocky Mountain spotted fever: Evidence for superiority of tetracyclines for therapy
27. Hidden mortality attributable to Rocky Mountain spotted fever: Immunohistochemical detection of fatal, serologically unconfirmed disease
28. Fatal Rocky Mountain spotted fever
29. T cell immunosenescence in vitro and in vivo
30. Rocky Mountain spotted fever: A clinical dilemma
31. Rocky Mountain spotted fever in the elderly
32. The role of host factors in the severity of spotted fever and typhus rickettsioses
33. Rocky Mountain spotted fever: Epidemiological and early clinical signs are keys to treatment and reduced mortality
34. Consequences of delayed diagnosis of Rocky Mountain spotted fever in children - West Virginia, Michigan, Tennessee, and Oklahoma, May-July 2000
35. Therapeutic delay and mortality in cases of Rocky Mountain spotted fever
36. The epidemiology of Rocky Mountain spotted fever
37. A review of Rocky Mountain spotted fever (tick-borne typhus), its agent, and its tick vectors in the United States
38. Black-white differences in infectious disease mortality in the United States
39. Fulminant Rocky Mountain spotted fever. Its pathologic characteristics associated with glucose-6-phosphate dehydrogenase deficiency
40. Fatal cases of Rocky Mountain spotted fever in the United States, 1981-1988
41. Rocky Mountain spotted fever: Diagnostic dilemma of the atypical presentation
42. Rocky Mountain spotted fever
43. Infections with Ehrlichia chaffeensis and Ehrlichia ewingii in persons coinfected with HIV
44. The sensitivity of various serologic tests in the diagnosis of Rocky Mountain spotted fever
45. Detection of Rickettsia rickettsii DNA in clinical specimens by using polymerase chain reaction technology
46. Surveillance of Rocky Mountain spotted fever in the United States, 1978-1980
47. Rickettsial diseases of childhood
48. Rocky Mountain spotted fever: A clinical review based on 48 confirmed cases, 1943-1986
49. Changing ecology of Rocky Mountain spotted fever
50. Epidemiology of rickettsial diseases
51. Widespread, simultaneous increase in the incidence of spotted fever group rickettsioses
52. DDT use and the incidence of Rocky Mountain spotted fever: An hypothesis
53. Rocky Mountain spotted fever: A note on some aspects of its epidemiology
54. Lethal effect of Rickettsia rickettsii on its tick vector (Dermacentor andersoni)
55. Nonpathogenic rickettsiae in Dermacentor andersoni: A limiting factor for the distribution of Rickettsia rickettsii
56. Rickettsia peacockii sp. nov., a new species infecting wood ticks, Dermacentor andersoni, in western Montana
57. Changing pattern in the incidence of Rocky Mountain spotted fever on Long Island (1971-1976)
58. Rocky Mountain spotted fever on Long Island. Epidemiologic and clinical aspects
59. Rocky Mountain spotted fever in Clermont County, Ohio
60. Rocky Mountain spotted fever in Georgia, 1961-1975: Analysis of social and environmental factors affecting occurrence
61. Rocky Mountain spotted fever in the United States, 1975-1977